Evaluate the Safety and Immunogenicity After MG1111 as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st SUDUVAX Inj. Vaccination
Condition: Varicella Interventions: Biological: MG1111 (BARICELA); Biological: VARIVAX; Biological: Suduvax Sponsor: Green Cross Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials